Aripiprazole Sandoz

Riik: Euroopa Liit

keel: inglise

Allikas: EMA (European Medicines Agency)

Osta kohe

Infovoldik Infovoldik (PIL)
27-02-2024
Toote omadused Toote omadused (SPC)
27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande (PAR)
25-09-2015

Toimeaine:

aripiprazole

Saadav alates:

Sandoz GmbH

ATC kood:

N05AX12

INN (Rahvusvaheline Nimetus):

aripiprazole

Terapeutiline rühm:

Psycholeptics

Terapeutiline ala:

Schizophrenia; Bipolar Disorder

Näidustused:

Aripiprazole Sandoz is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Aripiprazole Sandoz is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Aripiprazole Sandoz is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.,

Toote kokkuvõte:

Revision: 9

Volitamisolek:

Authorised

Loa andmise kuupäev:

2015-08-20

Infovoldik

                                54
B. PACKAGE LEAFLET
55 PACKAGE LEAFLET: INFORMATION FOR THE USER
ARIPIPRAZOLE SANDOZ 5 MG TABLETS
ARIPIPRAZOLE SANDOZ 10 MG TABLETS
ARIPIPRAZOLE SANDOZ 15 MG TABLETS
ARIPIPRAZOLE SANDOZ 20 MG TABLETS
ARIPIPRAZOLE SANDOZ 30 MG TABLETS
aripiprazole
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even
if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not
listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Aripiprazole Sandoz tablets are and what they are used for
2.
What you need to know before you take Aripiprazole Sandoz tablets
3.
How to take Aripiprazole Sandoz tablets
4.
Possible side effects
5.
How to store Aripiprazole Sandoz tablets
6.
Contents of the pack and other information
1.
WHAT ARIPIPRAZOLE SANDOZ IS AND WHAT IT IS USED FOR
Aripiprazole Sandoz contains the active substance aripiprazole and
belongs to a group of medicines called
antipsychotics. It is used to treat adults and adolescents aged 15
years and older who suffer from a disease
characterised by symptoms such as hearing, seeing or sensing things
which are not there, suspiciousness,
mistaken beliefs, incoherent speech and behaviour and emotional
flatness. People with this condition may
also feel depressed, guilty, anxious or tense.
Aripiprazole Sandoz is used to treat adults and adolescents aged 13
years and older who suffer from a
condition with symptoms such as feeling "high", having excessive
amounts of energy, needing much less
sleep than usual, talking very quickly with racing ideas and sometimes
severe irritability. In adults it also
prevents this condition from returning in patients who have responded
to the treatment w
                                
                                Lugege kogu dokumenti
                                
                            

Toote omadused

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Aripiprazole Sandoz 5 mg tablets
Aripiprazole Sandoz 10 mg tablets
Aripiprazole Sandoz 15 mg tablets
Aripiprazole Sandoz 20 mg tablets
Aripiprazole Sandoz 30 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Aripiprazole Sandoz 5 mg tablets
Each tablet contains 5 mg of aripiprazole.
Excipient with known effect
67.47 mg lactose (as monohydrate) per tablet.
Aripiprazole Sandoz 10 mg tablets
Each tablet contains 10 mg of aripiprazole.
Excipient with known effect
62.67 mg lactose (as monohydrate) per tablet.
Aripiprazole Sandoz 15 mg tablets
_ _
Each tablet contains 15 mg of aripiprazole.
Excipient with known effect
92.86 mg lactose (as monohydrate) per tablet.
Aripiprazole Sandoz 20 mg tablets
Each tablet contains 20 mg of aripiprazole.
Excipient with known effect
125.72 mg lactose (as monohydrate) per tablet.
Aripiprazole Sandoz 30 mg tablets
Each tablet contains 30 mg of aripiprazole.
Excipient with known effect
186.68 mg lactose (as monohydrate) per tablet.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Aripiprazole Sandoz 5 mg tablets
3
Blue coloured, mottled, round shaped tablet, with an approximate
diameter of 6.0 mm, debossed with “SZ”
on one side and “444” on the other side.
Aripiprazole Sandoz 10 mg tablets
Pink coloured, mottled, round shaped tablet, with an approximate
diameter of 6.0 mm, debossed with “SZ”
on one side and “446” on the other side.
Aripiprazole Sandoz 15 mg tablets
Yellow coloured, mottled, round shaped tablet, with an approximate
diameter of 7.0 mm, debossed with
“SZ” on one side and “447” on the other side.
Aripiprazole Sandoz 20 mg tablets
White coloured, round shaped tablet, with an approximate diameter of
7.8 mm, debossed with “SZ” on one
side and “448” on the other side.
_ _
_ _
Aripiprazole Sandoz 30 mg tablets
Pink coloured, mottled, round shaped tablet, with an approximate
diameter of 9.0 mm, debossed with “SZ”
on one side and 
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Infovoldik Infovoldik bulgaaria 27-02-2024
Toote omadused Toote omadused bulgaaria 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande bulgaaria 25-09-2015
Infovoldik Infovoldik hispaania 27-02-2024
Toote omadused Toote omadused hispaania 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande hispaania 25-09-2015
Infovoldik Infovoldik tšehhi 27-02-2024
Toote omadused Toote omadused tšehhi 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande tšehhi 25-09-2015
Infovoldik Infovoldik taani 27-02-2024
Toote omadused Toote omadused taani 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande taani 25-09-2015
Infovoldik Infovoldik saksa 27-02-2024
Toote omadused Toote omadused saksa 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande saksa 25-09-2015
Infovoldik Infovoldik eesti 27-02-2024
Toote omadused Toote omadused eesti 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande eesti 25-09-2015
Infovoldik Infovoldik kreeka 27-02-2024
Toote omadused Toote omadused kreeka 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande kreeka 25-09-2015
Infovoldik Infovoldik prantsuse 27-02-2024
Toote omadused Toote omadused prantsuse 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande prantsuse 25-09-2015
Infovoldik Infovoldik itaalia 27-02-2024
Toote omadused Toote omadused itaalia 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande itaalia 25-09-2015
Infovoldik Infovoldik läti 27-02-2024
Toote omadused Toote omadused läti 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande läti 25-09-2015
Infovoldik Infovoldik leedu 27-02-2024
Toote omadused Toote omadused leedu 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande leedu 25-09-2015
Infovoldik Infovoldik ungari 27-02-2024
Toote omadused Toote omadused ungari 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande ungari 25-09-2015
Infovoldik Infovoldik malta 27-02-2024
Toote omadused Toote omadused malta 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande malta 25-09-2015
Infovoldik Infovoldik hollandi 27-02-2024
Toote omadused Toote omadused hollandi 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande hollandi 25-09-2015
Infovoldik Infovoldik poola 27-02-2024
Toote omadused Toote omadused poola 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande poola 25-09-2015
Infovoldik Infovoldik portugali 27-02-2024
Toote omadused Toote omadused portugali 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande portugali 25-09-2015
Infovoldik Infovoldik rumeenia 27-02-2024
Toote omadused Toote omadused rumeenia 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande rumeenia 25-09-2015
Infovoldik Infovoldik slovaki 27-02-2024
Toote omadused Toote omadused slovaki 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande slovaki 25-09-2015
Infovoldik Infovoldik sloveeni 27-02-2024
Toote omadused Toote omadused sloveeni 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande sloveeni 25-09-2015
Infovoldik Infovoldik soome 27-02-2024
Toote omadused Toote omadused soome 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande soome 25-09-2015
Infovoldik Infovoldik rootsi 27-02-2024
Toote omadused Toote omadused rootsi 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande rootsi 25-09-2015
Infovoldik Infovoldik norra 27-02-2024
Toote omadused Toote omadused norra 27-02-2024
Infovoldik Infovoldik islandi 27-02-2024
Toote omadused Toote omadused islandi 27-02-2024
Infovoldik Infovoldik horvaadi 27-02-2024
Toote omadused Toote omadused horvaadi 27-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande horvaadi 25-09-2015

Otsige selle tootega seotud teateid

Vaadake dokumentide ajalugu